Wall Street analysts expect that Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) will post earnings per share of ($0.69) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Diffusion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.90). Diffusion Pharmaceuticals posted earnings of ($0.75) per share in the same quarter last year, which suggests a positive year over year growth rate of 8%. The company is scheduled to issue its next earnings report on Monday, August 12th.
According to Zacks, analysts expect that Diffusion Pharmaceuticals will report full year earnings of ($2.27) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($2.25). For the next financial year, analysts anticipate that the company will post earnings of ($1.48) per share, with EPS estimates ranging from ($1.57) to ($1.39). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Diffusion Pharmaceuticals.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last posted its earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.09.
DFFN has been the topic of several research reports. HC Wainwright increased their target price on Diffusion Pharmaceuticals to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. ValuEngine downgraded Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.
An institutional investor recently raised its position in Diffusion Pharmaceuticals stock. Renaissance Technologies LLC boosted its stake in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) by 108.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,070 shares of the company’s stock after purchasing an additional 56,230 shares during the quarter. Renaissance Technologies LLC owned approximately 3.20% of Diffusion Pharmaceuticals worth $401,000 as of its most recent SEC filing. 6.20% of the stock is currently owned by hedge funds and other institutional investors.
DFFN traded down $0.32 during mid-day trading on Friday, hitting $2.83. 299,145 shares of the stock were exchanged, compared to its average volume of 135,470. Diffusion Pharmaceuticals has a 1-year low of $1.83 and a 1-year high of $11.00. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.02. The firm has a market cap of $9.57 million, a price-to-earnings ratio of -0.47 and a beta of 0.05.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Recommended Story: What does cost of debt say about a company’s financial health?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.